Interim Report January – March 2020
First quarter in brief·Net sales totaled SEK 11,475 (11,931) thousand. Adjusted for the bioprocess order during the first quarter of 2019, which totaled SEK 2.4 million, growth for the quarter was 20%. · Gross profit was SEK 10,977 (11,140) thousand. · Operating profit/loss before depreciation and amortization (EBITDA) totaled SEK -847 (2,695) thousand. Non-recurring expenses relating to the ongoing acquisition of QED Bioscience Inc. had a negative impact on operating profit of SEK 1,354 thousand. · Operating profit/loss was SEK -1,889 (1,942) thousand. · Comprehensive